Last reviewed · How we verify
CPL409116
At a glance
| Generic name | CPL409116 |
|---|---|
| Sponsor | Celon Pharma SA |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis (PHASE2)
- Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CPL409116 CI brief — competitive landscape report
- CPL409116 updates RSS · CI watch RSS
- Celon Pharma SA portfolio CI